Collectively, we observed significant DNA damage in NSCLC treatment with the USP5 inhibitor EOAI, as well as cell cycle arrest, apoptosis, and autophagy induced by p53 transcription factor activation. The gene discussed is USP5; the disease is non-small cell lung carcinoma.